T2	Participants 767 886	Patients with septic shock who were enrolled in the placebo limb of the North American Sepsis Trial (NORASEPT II) study
T1	Participants 78 90	septic shock
T3	Participants 627 648	septic shock patients
T4	Participants 998 1030	Nine hundred and thirty patients
T5	Participants 1684 1750	patients' mean age (+/- SD) was 59 +/- 17 years (range, 18 to 102)
